Hua Medicine Soars with HuaTangNing Sales Surge

Hua Medicine (HK:2552) has released an update.

Hua Medicine has reported substantial growth with its HuaTangNing product’s sales volume increasing to 846,000 packs in the first half of 2024, a significant rise from 212,000 packs in the same period last year, resulting in a 46% revenue increase to RMB102.7 million. Despite a price reduction from entering China’s National Reimbursement Drug List, the company’s gross profit margin stands at 46.5%. Additionally, Hua Medicine is expanding dorzagliatin manufacturing capacity and progressing with post-marketing clinical studies, indicating a positive long-term outlook for the drug.

For further insights into HK:2552 stock, check out TipRanks’ Stock Analysis page.